ONCOLife is a next-gen news and communication platform. We’re committed to providing trusted news and firsthand reports from reliable sources.
United States
Joined March 2016
- Tweets 1,827
- Following 3,330
- Followers 703
- Likes 339
DYNAMIC-III trial show that circulating #tumor DNA (#ctDNA) testing can transform post-surgical care in #coloncancer. ctDNA- individuals achieved 87% 3 year recurrence-free survival with reduced #chemotherapy while ctDNA+ faced a 50% recurrence risk
healthandpharma.net/ctdna-bl…
Findings from the ASCENT-03 trial show that #sacituzumab govitecan (#Trodelvy) significantly reduced the risk of disease progression or death by 38% compared with #chemotherapy in untreated metastatic triple-negative #breastcancer patients...
healthandpharma.net/trodelvy…
ONCOLife retweeted
RESPECT Trial (1,287 pts, 10-yr follow-up):
• Trastuzumab alone: 88.5% success
• + Chemo: 90.2% → Minimal difference!
HER2DX Genomic Test:
• 74% low-risk: 86% 10-yr survival without chemo
• 26% high-risk: +15% benefit with chemo
Personalized spares toxicity.
@Larvol @OncoAlert @ozdogan_md @Nature #breastcancer #her2
ESMO’s new #ELCAP guidance distills 23 consensus statements from 20 experts to safely integrate #AI into #cancer care. It categorizes #LLMs as patient-facing, clinician-facing, requiring human oversight, local validation and continuous monitoring.
healthandpharma.net/esmo-ai-…
ONCOLife retweeted
NEJM reports 10-year results of the SUPREMO trial:
PMRT modestly reduced locoregional recurrence but didn’t improve OS in intermediate-risk #breastcancer
Importance of individualized treatment decisions reaffirmed.
@OncoAlert #Oncology @Larvol @oncodaily @stolaney1 @brunolarvol @ONCOLife_HP
Results from TROPION-B02 trial, presented at #ESMO25 show that #Datroway (#datopotamab #deruxtecan) significantly extended OS by 5 months and doubled PFS versus #chemotherapy in patients with MTN #breastcancer ineligible for #immunotherapy. healthandpharma.net/datroway…
ONCOLife retweeted
Biochemical recurrence isn’t just relapse!
Next-gen imaging like PSMA PET now reveals “PSMA+BCR,” a hidden state between local and metastatic disease.
The NCI Working Group urges trials to rethink control arms, endpoints, and toxicity, less intensity, more precision. @theNCI @ASCO @JCO_ASCO @Dr_RaviMadan @APCCC_Lugano @OncBrothers #ProstateCancer
A new study presented at #ESMO25 suggests that #thymus may hold one of the missing keys to #immunotherapy response. #Cancer patients with healthier #thymic function experienced better outcomes with immune #checkpointinhibitors across multiple #tumor types
healthandpharma.net/esmo25-a…
ONCOLife retweeted
Just in from #ESMO25 Berlin👉Phase III PSMAAddition trial shows that adding ¹⁷⁷Lu-PSMA-617 to ADT + ARPI significantly improved rPFS (HR 0.72; p = 0.002) in PSMA-positive mHSPC, with consistent benefit across subgroups. OS immature.
#ProstateCancer @OncoAlert @UroToday
ONCOLife retweeted
Breaking news from #ESMO25👉Improved OS in high risk biochemical recurrent #ProstateCancer on with ENZA+ADT vs ADT alone, HR: 0.59 (no OS benefit with ENZA monotherapy), 👏wonderful news for our pts👉congrats @SFreedlandMD @nealshore & the team. @OncoAlert @urotoday @PCF_Science
ONCOLife retweeted
📌 Patient-reported outcomes from the SERENA-6 trial of CAMI+ CDK4/6i for emergent ESR1m during first-line (1L) endocrine-based therapy and ahead of disease progression in pts with HR+/HER2– advanced breast cancer.
Mini oral session 🔛#ESMO25
@OncoAlert #OncoAlertAF @elmayermd @DFCI_BreastOnc
ONCOLife retweeted
Terrific talk by @dmukherji #ESMO 👉Optimizing use of endocrine therapy and chemotherapy in mCRPC #prostatecancer 👉need to improve implementation of level-1 evidence, manage bone and CV toxicities & sequencing of therapy👇@OncoAlert @urotoday
Five-year follow-up results from the P3 Study 309/ #KEYNOTE-775, presented at #ESMO25, confirm that #lenvatinib plus #pembrolizumab delivers a durable survival advantage over chemotherapy in advanced #endometrialcarcinoma.
healthandpharma.net/esmo25-l…
ONCOLife retweeted
In muscle-invasive bladder cancer, ctDNA-guided adjuvant atezolizumab improved disease-free and overall survival.
Proud to be part of this work, with @tompowles1 and all colleagues, patients, families, and sponsors who made it real.
@NEJM @myESMO #ESMO25 @OncoBellmunt
@TeresaSAmaral @E_de_Azambuja @JyotiBajpai01 @ArBayle @Ecastromarcos @GillSharlene @PGrivasMDPhD @ErikaHamilton9 @DrAngelaLamarca @DrJonLim @StephenVLiu @LoiSher @DrJNaidoo @NReguart @LorenzaRimassa @Rodrosb @LizzySmyth1 @pawel_sobczuk @PTarantinoMD @darioT_ @ArndtVogel @TiansterZhang
#ESMOAmbassadors #ESMO25
@neerajaiims @yekeduz_emre @tompowles1 @OncoAlert @ONCOassist @OncBrothers @dmukherji @curijoey @DrChoueiri
ONCOLife retweeted
Impressive results from #ESMO25!
Dr. Jun Guo presented RC48-C016 ph3👉Disitamab Vedotin + Toripalimab in 1L HER2+ mUC #bladdercancer vs chemo👉PFS: 13.1 vs 6.5 mo (HR 0.36), OS: 31.5 vs 16.9 mo (HR 0.54). Gr ≥3 TRAE 55% vs 87%)
A potential new SOC! @OncoAlert @UroToday
ONCOLife retweeted
Honored to join this inspiring panel of ASCO leaders. Grateful to everyone building bridges between policy and patient care. #Advocacy #Equity #ASCO @ASCO @healthpolicycop @JasmineKambojMD
Stay tuned for our very first Webinar, organized by our Subcommittee leaders!
@yuan_ruiling @WadeSwenson @Noha_Soror @ASCO @ErulEnes @JasmineKambojMD @HemOncFellows @HemOncWomenDocs @IMG_Oncologists
ONCOLife retweeted
Day 3 #ESMO25 | TROPION-Breast02
In 1L locally recurrent inoperable/metastatic TNBC not eligible for PD-(L)1i, Dato-DXd versus investigator’s choice chemo: significant improvements in both PFS and OS (first time ever OS benefit in this setting) and safety consistent with prior trials.
@ESMO_Open @myESMO @JavierCortesMD @E_de_Azambuja @Larvol @OncoAlert #esmo25
ONCOLife retweeted
#ESMO25
TROPION-Breast02 (Dato-DXd vs CT, 1L PD-(L)1–ineligible mTNBC)
Dato-DXd markedly improved outcomes vs chemo — mPFS 10.8 vs 5.6 mo (HR 0.57), ORR 62% vs 29%, with no grade 5 TRAEs and a confirmed OS benefit.
I think Dato-DXd is clearly ahead of SG!!👏👏👏
ONCOLife retweeted
#PresidentialSession | Day 3 #ESMO25
HARMONi-6
Ivonescimab + chemo significantly improved PFS vs tislelizumab + chemo in 1L squamous #NSCLC
👍mPFS 11.1 vs 6.9 mo (HR 0.60; 95% CI 0.46-0.78; p<.0001)
Benefit consistent across PD-L1 subgroups.
Manageable safety.
@Larvol @ozdogan_md @OncoAlert @OncoDailyIO @OncLive
#LungCancer #Immunotherapy
ONCOLife retweeted
A wonderful discussion by Dr. Ana Garrido-Castro @DFCI_BreastOnc on 1L TROP2 ADC in TNBC. New standard of care for 1L PD-L1 negative TNBC? new horizon for TNBC and so many consideration related to toxicity profile, ORR, crossover, early recurrence, drug access. @OncoAlert #ESMO25
